Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Atreca Inc | BCEL | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
0.15 |
Trades | Shares Traded | Average Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 0.1023 - 1.35 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
- | 0 | US$ 0.15 | USD |
Atreca Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
5.94M | 39.62M | - | 0 | -97.16M | -2.45 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Atreca News
Date | Time | Source | News Article |
---|---|---|---|
3/11/2024 | 15:12 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting.. |
3/11/2024 | 15:10 | Edgar (US Regulatory) | Form 8-K - Current report |
2/06/2024 | 15:00 | Edgar (US Regulatory) | Form 8-K - Current report |
1/05/2024 | 15:57 | Edgar (US Regulatory) | Form PREM14A - Preliminary proxy statements relating to.. |
12/26/2023 | 07:39 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting.. |
12/26/2023 | 07:38 | Edgar (US Regulatory) | Form 8-K - Current report |
12/26/2023 | 07:30 | GlobeNewswire Inc. | Atreca Announces Asset Purchase Agreement for Sale of.. |
11/14/2023 | 15:30 | GlobeNewswire Inc. | Atreca Reports Third Quarter 2023 Financial Results and.. |
9/27/2023 | 18:20 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of.. |
9/21/2023 | 07:01 | Edgar (US Regulatory) | Form 8-K - Current report |
9/21/2023 | 07:00 | GlobeNewswire Inc. | Atreca Announces Agreement to Terminate Lease and Departure.. |
9/14/2023 | 15:01 | Edgar (US Regulatory) | Form 8-K - Current report |
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BCEL Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
1 Month | 0.2619 | 0.2849 | 0.15 | 0.2082208 | 621,044 | -0.1119 | -42.73% |
3 Months | 0.1275 | 0.4448 | 0.1023 | 0.2746614 | 9,925,709 | 0.0225 | 17.65% |
6 Months | 0.292 | 0.6562 | 0.1023 | 0.2809444 | 5,596,964 | -0.142 | -48.63% |
1 Year | 1.24 | 1.35 | 0.1023 | 0.2953461 | 2,812,529 | -1.09 | -87.90% |
3 Years | 14.98 | 15.55 | 0.1023 | 1.65 | 1,290,389 | -14.83 | -99.00% |
5 Years | 19.90 | 29.35 | 0.1023 | 2.87 | 877,489 | -19.75 | -99.25% |
Atreca Description
Atreca is a biotechnology company that develops novel therapeutics through a deep understanding of the human immune response with a focus on innovative novel cancer immunotherapeutics. With its Immune Repertoire Capture IRC technology Atreca has an unparalleled insight into how cancer patients immune responses can drive better clinical outcomes. Atreca was founded by scientists industry experts and investors who share the vision that unlocking the immune response of todays patients is the key to creating a new generation of therapies. Atreca is looking for talented entrepreneurial people who are dedicated to making a positive impact on human health. |